A randomized surgical window-of-opportunity trial found that giving dual immune checkpoint blockade before resection in recurrent glioblastoma increased tumor T-cell infiltration and was associated with extended patient survival. The work, published in Nature Communications, links the pre-operative timing to measurable immune remodeling. The study strengthens the case for neoadjuvant immunotherapy approaches in brain tumors, where post-surgical immune access and timing can constrain efficacy. For drug developers, the data provides a practical framework for translating “immune-priming” into measurable tissue readouts before standard surgical pathways.